These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 14632767)

  • 1. New insights into the pathophysiology and management of bone disease in multiple myeloma.
    Terpos E; Politou M; Rahemtulla A
    Br J Haematol; 2003 Dec; 123(5):758-69. PubMed ID: 14632767
    [No Abstract]   [Full Text] [Related]  

  • 2. Role of the bone marrow microenvironment in multiple myeloma.
    Roodman GD
    J Bone Miner Res; 2002 Nov; 17(11):1921-5. PubMed ID: 12412796
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New insights into role of microenvironment in multiple myeloma.
    Tricot G
    Lancet; 2000 Jan; 355(9200):248-50. PubMed ID: 10675068
    [No Abstract]   [Full Text] [Related]  

  • 4. The high rate of bone resorption in multiple myeloma is due to RANK (receptor activator of nuclear factor-kappaB) and RANK Ligand expression.
    Roux S; Mariette X
    Leuk Lymphoma; 2004 Jun; 45(6):1111-8. PubMed ID: 15359989
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Bone disease in multiple myeloma and its mechanism].
    Abe M
    Clin Calcium; 2006 Apr; 16(4):565- 71. PubMed ID: 16582506
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Receptor activator of NF-kappaB ligand, macrophage inflammatory protein-1alpha, and the proteasome: novel therapeutic targets in myeloma.
    Oyajobi BO; Mundy GR
    Cancer; 2003 Feb; 97(3 Suppl):813-7. PubMed ID: 12548580
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New insights in myeloma-induced osteolysis.
    Barillé-Nion S; Bataille R
    Leuk Lymphoma; 2003 Sep; 44(9):1463-7. PubMed ID: 14565645
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Clinical implications of new insights into the regulation of bone resorption].
    Lems WF; Bijlsma JW
    Ned Tijdschr Geneeskd; 2005 Jul; 149(30):1664-7. PubMed ID: 16104110
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New insight in the mechanism of osteoclast activation and formation in multiple myeloma: focus on the receptor activator of NF-kappaB ligand (RANKL).
    Giuliani N; Colla S; Rizzoli V
    Exp Hematol; 2004 Aug; 32(8):685-91. PubMed ID: 15308315
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pathophysiology of RANK ligand (RANKL) and osteoprotegerin (OPG).
    Hofbauer LC
    Ann Endocrinol (Paris); 2006 Apr; 67(2):139-41. PubMed ID: 16639364
    [No Abstract]   [Full Text] [Related]  

  • 11. Bone disease in multiple myeloma.
    Hjertner Ø; Standal T; Børset M; Sundan A; Waage A
    Med Oncol; 2006; 23(4):431-41. PubMed ID: 17303901
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Update on the pathogenesis of osteolysis in multiple myeloma patients.
    Giuliani N; Colla S; Rizzoli V
    Acta Biomed; 2004 Dec; 75(3):143-52. PubMed ID: 15796087
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evidence of a role for RANKL in the development of myeloma bone disease.
    De Leenheer E; Mueller GS; Vanderkerken K; Croucher PI
    Curr Opin Pharmacol; 2004 Aug; 4(4):340-6. PubMed ID: 15251126
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Receptor activator of nuclear factor-kappaB ligand and osteoprotegerin: potential implications for the pathogenesis and treatment of malignant bone diseases.
    Hofbauer LC; Neubauer A; Heufelder AE
    Cancer; 2001 Aug; 92(3):460-70. PubMed ID: 11505389
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multiple myeloma.
    Schneider HG; Sentry J
    N Engl J Med; 2005 Feb; 352(8):840-1; author reply 840-1. PubMed ID: 15736296
    [No Abstract]   [Full Text] [Related]  

  • 16. Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells.
    Shipman CM; Croucher PI
    Cancer Res; 2003 Mar; 63(5):912-6. PubMed ID: 12615702
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of new targets for therapy of osteolytic bone disease in multiple myeloma.
    Hjertner Ø; Standal T; Børset M; Sundan A; Waage A
    Curr Drug Targets; 2005 Sep; 6(6):701-11. PubMed ID: 16178802
    [TBL] [Abstract][Full Text] [Related]  

  • 18. RANKL-RANK signaling in osteoclastogenesis and bone disease.
    Wada T; Nakashima T; Hiroshi N; Penninger JM
    Trends Mol Med; 2006 Jan; 12(1):17-25. PubMed ID: 16356770
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Revisiting the seed and soil theory of bone metastasis: new tools, same answer.
    Kostenuik PJ
    J Musculoskelet Neuronal Interact; 2004 Dec; 4(4):375-6. PubMed ID: 15758267
    [No Abstract]   [Full Text] [Related]  

  • 20. Autologous stem cell transplantation normalizes abnormal bone remodeling and sRANKL/osteoprotegerin ratio in patients with multiple myeloma.
    Terpos E; Politou M; Szydlo R; Nadal E; Avery S; Olavarria E; Kanfer E; Goldman JM; Apperley JF; Rahemtulla A
    Leukemia; 2004 Aug; 18(8):1420-6. PubMed ID: 15215875
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.